Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

In Brief: Estee Lauder/Donna Karan

This article was originally published in The Rose Sheet

  • News
  • The Rose Sheet

Executive Summary

Estee Lauder/Donna Karan: Licensing agreement giving Lauder exclusive worldwide rights to manufacture, distribute, market and sell beauty products under the Donna Karan New York and DKNY trademarks closed Nov. 10. Following a transition period, Estee Lauder will assume sales to retailers Feb. 1, Karan announced. Estee Lauder USA President and CEO Robin Burns will head the Donna Karan beauty division ("The Rose Sheet" Oct. 6, p. 5). In a Nov. 11 announcement, Donna Karan said it would eliminate 79 positions in its beauty division related to the spin off...

Table

View full table

Tags:
Latest Headlines

China Biotech Podcast: AACR, BIOSECURE European Perspectives

Gilead Doesn’t See Big M&A In Near-Term, But Eyes Next-Gen Cell Therapies

BMS Will Cut $1.5bn And 2,200 Jobs To Reinvest In Needed Growth

AbbVie Claims Rinvoq Superiority To Dupixent In AD

See All
UsernamePublicRestriction

Register

RS004851

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By